Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer

Both 5-methylcytosine （5mC） and its oxidized form 5-hydroxymethylcytosine （5hmC） have been proposed to be involved in tumorigenesis. Because the readout of the broadly used 5mC mapping method, bisulfite sequencing （BS-seq）, is the sum of 5mC and 5hmC levels, the 5mC/5hmC patterns and relationship of these two modifications remain poorly understood. By profiling real 5mC （BS-seq corrected by Tet-assisted BS-seq, TAB-seq） and 5hmC （TAB-seq） levels simultaneously at single-nucleotide resolution, we here demonstrate that there is no global loss of 5mC in kidney tu- mors compared with matched normal tissues. Conversely, 5hmC was globally lost in virtually all kidney tumor tissues. The 5hmC level in tumor tissues is an independent prognostic marker for kidney cancer, with lower levels of 5hmC as- sociated with shorter overall survival. Furthermore, we demonstrated that loss of 5hmC is linked to hypermethylation in tumors compared with matched normal tissues, particularly in gene body regions. Strikingly, gene body hypermeth- ylation was significantly associated with silencing of the tumor-related genes. Downregulation of IDH1 was identified as a mechanism underlying 5hmC loss in kidney cancer. Restoring 5hmC levels attenuated the invasion capacity of tumor ceils and suppressed tumor growth in a xenograft model Collectively, our results demonstrate that loss of 5hmC is both a prognostic marker and an oncogenie event in kidney cancer by remodeling the DNA methylation pattern.